XENE

Xenon Pharmaceuticals Inc. (XENE) | Rumor.io

Xenon Pharmaceuticals

XENE

Attention (50-day avg)0%

Attention rank (50-day avg)#1,143

Bullish sentiment (50-day avg)45%

Price to earnings ratio-8.42

Market capitalization3.6B

Earnings per share-4.74

Dividend yield (TTM)—

Revenue (annual)7.5M

Net income (annual)-345.9M

Social

What share of all stock conversation is about XENE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% -0.01	0% +0	0% +0

Sep 18

Xenon Pharmaceuticals ($XENE) has voluntarily paused new patient enrollment in its ongoing Phase 3 trials for major depressive disorder and bipolar depression due to reports of neuropsychiatric adverse events.
The company has submitted a New Drug Application to the FDA for its investigational drug azetukalner to treat focal seizures, with clinical data from Phase 2b X-TOLE and Phase 3 X-TOLE2 studies showing a statistically significant reduction in monthly seizure frequency.
Analysts, including William Blair, consider the stock reaction to be overblown, noting that similar incidence rates of psychosis have been reported on the label of blockbuster antidepressants, but no black box warning has been issued.

Generated by AI

Sentiment

Of the messages about XENE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	95% +73.64	30.04% -60.23	82.5% -6.72
Bearish	100%	5% -73.64	69.96% +60.23	17.5% +6.72

Bullish· Mar 10

$XENE's recent surge of 50% on positive epilepsy trial data demonstrates the potential for explosive growth in the company.
The company's $500M offering post-catalyst is a classic volatility play, indicating that investors are willing to take on risk in pursuit of high returns.
Xenon Pharmaceuticals' strong earnings beat and positive catalyst have led to a shift in market structure, with the company now in a position of bull domination.

Bearish· Oct 19

Institutional holdings in XENON Pharmaceuticals Inc. have dropped from 90% to 67.68%.
The company is expected to report a significant loss of $25-30 million in its upcoming earnings report.
XENON Pharmaceuticals Inc. has a history of not being profitable, and the FDA has never approved one of its products, making it a high-risk investment.

Generated by AI

Topics

Of the messages about XENE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	81.08%	82.96%
Analysts	—	100%	14.05%	10.57%
Earnings	—	0%	0%	0.48%
Controversies	—	0%	3.24%	0.36%
Technical Analysis	—	0%	1.62%	5.64%
Macro	—	0%	0%	0%

Announcements· Mar 11

Xenon Pharmaceuticals Inc. (XENE) has priced its upsized public offering of $650.0 million at $57 per share, increasing from an initial $500 million.
The company's inhibitor portfolio includes CitroTech 34, a patented fire-prevention formula, and its IL-17A/F inhibitor, Bimzelx, shows statistically significant superiority over Skyrizi in psoriatic arthritis trials.
The deal size was increased to $650 million in common stock from $500 million, with joint book running managers including JPMorgan, Jefferies, and TD Cowen.

Technical Analysis· Oct 7

$XENE is forming a broadening tops pattern, which could indicate a reversal in its upward trend.
The stock's RSI is overbought at 78, suggesting a potential correction or reversal in its price movement.
A double inside day was observed, which could be a sign of a potential reversal or a continuation of the current trend.

Generated by AI

Community

Of the messages about XENE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	43.9%	49.29%	52.44%
Newcomers	100%	56.1%	50.71%	47.56%

Regulars· Sep 18

Xenon Pharmaceuticals Inc. has submitted a New Drug Application to the FDA for its investigational drug azetukalner to treat focal seizures, with clinical data from Phase 2b and Phase 3 studies showing a statistically significant reduction in monthly seizure frequency.
The company has paused new patient enrollment in ongoing depression studies due to observed neuropsychiatric adverse events, but this pause does not impact epilepsy studies, and analysts note that the events are consistent with the known profile of azetukalner.
Despite the pause, analysts remain optimistic about the potential of azetukalner in focal onset epilepsy, citing the impressive Phase 3 results, and several firms have lowered their price targets for Xenon Pharmaceuticals Inc. but still maintain a positive outlook.

Newcomers· Sep 18

The company's Phase 3 trial for its epilepsy treatment was voluntarily paused due to high risk, leading to a significant stock price drop.
The pause in the trial and the resulting stock price decline are causing concern among investors, with some speculating about the potential impact on the company's timeline.
Despite the current stock price, many analysts believe that Xenon Pharmaceuticals' price targets are still relatively high, with some predictions as high as $90.

Generated by AI

News

Why This Biotech Just Erased Its One-Day 50% Pop

Xenon Pharmaceuticals voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects.

11d agoInvestor's Business Daily

Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.

11d agoBarron's

Xenon Pharma stock tumbles on psychiatry trial pause

12d agoInvesting.com

Xenon to Present at Wells Fargo Healthcare Conference

VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: Wells Fargo Healthcare Conference, Boston, MAFireside Chat: Wednesday, September 9, 11:00–11:30 am ET Details about the presentation, inc

26d agoYahoo! Finance Canada

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 13,450 share options and 7,850 restricted share units (RSUs). All of the foregoing share options and RSUs were app

1mo agoYahoo! Finance Canada

Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity (XENE)

1mo agoSeeking Alpha

Also Discussed

Investors talking about XENE also mention

#	Name	Attention
1	Dianthus Therapeutics Inc.DNTH	0%0
2	Nuvalent, Inc.NUVL	0%0
3	Vaxcyte Inc.PCVX	0%0
4	Edgewise Therapeutics Inc.EWTX	0%new
5	Zymeworks Inc.ZYME	0%0
6	MORF - Morphic Holding, Inc.	——
7	Relmada Therapeutics Inc.RLMD	0%0
8	INZY - Inozyme Pharma, Inc.	——
9	Praxis Precision Medicines, Inc.PRAX	0%0
10	EQRX - EQRx, Inc.	——

Xenon Pharmaceuticals Inc.

Healthcare
Biotechnology

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutics for patients with neurological and psychiatric disorders. The company's lead molecule, azetukalner, is a novel potent selective Kv7 potassium channel opener currently in Phase 3 clinical trials for treating epilepsy, major depressive disorder, and bipolar depression. Xenon's pipeline also includes early-stage potassium and sodium channel modulators, with Kv7 and Nav1.7 programs in Phase 1 development for pain management. The company addresses areas of high unmet medical need in rare central nervous system conditions and other neurological disorders. Headquartered in Burnaby, British Columbia, with additional offices in Boston, Massachusetts, Xenon operates as a clinical-stage biopharmaceutical company committed to improving the lives of patients living with complex neurological conditions.

Website

Location

200-3650 Gilmore Way

Burnaby, BC, V5G 4W8

Canada

Social

What share of all stock conversation is about XENE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% -0.01	0% +0	0% +0

Sep 18

Xenon Pharmaceuticals ($XENE) has voluntarily paused new patient enrollment in its ongoing Phase 3 trials for major depressive disorder and bipolar depression due to reports of neuropsychiatric adverse events.
The company has submitted a New Drug Application to the FDA for its investigational drug azetukalner to treat focal seizures, with clinical data from Phase 2b X-TOLE and Phase 3 X-TOLE2 studies showing a statistically significant reduction in monthly seizure frequency.
Analysts, including William Blair, consider the stock reaction to be overblown, noting that similar incidence rates of psychosis have been reported on the label of blockbuster antidepressants, but no black box warning has been issued.

Generated by AI

Sentiment

Of the messages about XENE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	95% +73.64	30.04% -60.23	82.5% -6.72
Bearish	100%	5% -73.64	69.96% +60.23	17.5% +6.72

Bullish· Mar 10

$XENE's recent surge of 50% on positive epilepsy trial data demonstrates the potential for explosive growth in the company.
The company's $500M offering post-catalyst is a classic volatility play, indicating that investors are willing to take on risk in pursuit of high returns.
Xenon Pharmaceuticals' strong earnings beat and positive catalyst have led to a shift in market structure, with the company now in a position of bull domination.

Bearish· Oct 19

Institutional holdings in XENON Pharmaceuticals Inc. have dropped from 90% to 67.68%.
The company is expected to report a significant loss of $25-30 million in its upcoming earnings report.
XENON Pharmaceuticals Inc. has a history of not being profitable, and the FDA has never approved one of its products, making it a high-risk investment.

Generated by AI

Topics

Of the messages about XENE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	81.08%	82.96%
Analysts	—	100%	14.05%	10.57%
Earnings	—	0%	0%	0.48%
Controversies	—	0%	3.24%	0.36%
Technical Analysis	—	0%	1.62%	5.64%
Macro	—	0%	0%	0%

Announcements· Mar 11

Xenon Pharmaceuticals Inc. (XENE) has priced its upsized public offering of $650.0 million at $57 per share, increasing from an initial $500 million.
The company's inhibitor portfolio includes CitroTech 34, a patented fire-prevention formula, and its IL-17A/F inhibitor, Bimzelx, shows statistically significant superiority over Skyrizi in psoriatic arthritis trials.
The deal size was increased to $650 million in common stock from $500 million, with joint book running managers including JPMorgan, Jefferies, and TD Cowen.

Technical Analysis· Oct 7

$XENE is forming a broadening tops pattern, which could indicate a reversal in its upward trend.
The stock's RSI is overbought at 78, suggesting a potential correction or reversal in its price movement.
A double inside day was observed, which could be a sign of a potential reversal or a continuation of the current trend.

Generated by AI

Community

Of the messages about XENE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	43.9%	49.29%	52.44%
Newcomers	100%	56.1%	50.71%	47.56%

Regulars· Sep 18

Xenon Pharmaceuticals Inc. has submitted a New Drug Application to the FDA for its investigational drug azetukalner to treat focal seizures, with clinical data from Phase 2b and Phase 3 studies showing a statistically significant reduction in monthly seizure frequency.
The company has paused new patient enrollment in ongoing depression studies due to observed neuropsychiatric adverse events, but this pause does not impact epilepsy studies, and analysts note that the events are consistent with the known profile of azetukalner.
Despite the pause, analysts remain optimistic about the potential of azetukalner in focal onset epilepsy, citing the impressive Phase 3 results, and several firms have lowered their price targets for Xenon Pharmaceuticals Inc. but still maintain a positive outlook.

Newcomers· Sep 18

The company's Phase 3 trial for its epilepsy treatment was voluntarily paused due to high risk, leading to a significant stock price drop.
The pause in the trial and the resulting stock price decline are causing concern among investors, with some speculating about the potential impact on the company's timeline.
Despite the current stock price, many analysts believe that Xenon Pharmaceuticals' price targets are still relatively high, with some predictions as high as $90.

Generated by AI

Xenon Pharmaceuticals

Social

Sep 18

Bullish· Mar 10

Bearish· Oct 19

Announcements· Mar 11

Technical Analysis· Oct 7

Regulars· Sep 18

Newcomers· Sep 18

Why This Biotech Just Erased Its One-Day 50% Pop

Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.

Xenon Pharma stock tumbles on psychiatry trial pause

Xenon to Present at Wells Fargo Healthcare Conference

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity (XENE)

Also Discussed

Xenon Pharmaceuticals Inc.

Company Information

Location

Why This Biotech Just Erased Its One-Day 50% Pop

Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.

Xenon Pharma stock tumbles on psychiatry trial pause

Xenon to Present at Wells Fargo Healthcare Conference

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity (XENE)

Also Discussed

Social

Sep 18

Bullish· Mar 10

Bearish· Oct 19

Announcements· Mar 11

Technical Analysis· Oct 7

Regulars· Sep 18

Newcomers· Sep 18